To identify treatment factors that may affect the survival of children with inv(16)(p13.1q22), we compared the outcomes of 19 patients with this genetic feature treated at our institution during two treatment eras. Nine patients were treated during era 1 (1980 to 1987), and 10 were treated during era 2 (1988 to 1996). All entered complete remission (CR) with induction therapy. Eight of the nine children treated in era 1 died, seven of relapsed leukemia. In contrast, three of 10 patients treated during era 2 have died, all of non-disease-related causes. Eventfree survival (EFS) estimates were significantly higher for patients treated during era 2 than for those treated during era 1 (P = 0.03); the 6-year estimates were 70 ± 15% (s.e.) and 11 ± 7%, respectively. Era 2 treatment protocols differed from those of era 1 in their use of higher doses of cytarabine and etoposide during induction and consolidation chemotherapy and in their use of 2-chlorodeoxyadenosine (2-CDA). These results suggest that dose intensification of cytarabine benefits children with AML and inv(16), as is the case in adults. They also suggest that dose intensification of etoposide and addition of 2-CDA may also offer an advantage. This study underscores the dependence of the prognostic impact of cytogenetic features on the efficacy of treatment. Leukemia (2001) 15, 1326-1330.
Introduction
In acute myeloid leukemia (AML), cytogenetic features of the malignant cells at the time of diagnosis are recognized as one of the most important prognostic indicators. [1] [2] [3] [4] The inv(16)(p13.1q22) and t(16;16)(p13.1;q22) are usually associated with the French-American-British (FAB) M4Eo subtype of AML, myelomonocytic leukemia with eosinophilia. In general, these abnormalities are associated with favorable treatment outcomes in children and adults with AML. [4] [5] [6] [7] [8] [9] At our institution, however, children with AML and inv (16) who were treated between 1980 and 1987 fared no better than did other children with AML. 10 These children received cytarabine (Ara-C) at the standard dosage (200 mg/m 2 per day for 5 to 7 days) and etoposide (VP-16) during induction and post-remission therapy. 11, 12 Dose intensification of Ara-C chemotherapy was recently reported to improve the outcomes of adults with AML and inv (16) . 13, 14 Since 1987, our AML protocols have included higher doses of Ara-C and VP-16; 15 beginning in 1991, we also introduced 2-chlorodeoxyadenosine (2-CDA) as up-front window therapy. 16 To determine whether these changes in therapy improved the outcome of treatment, we reviewed the clinical features, and treatment outcomes of 19 children and adolescents with de novo AML and inv (16) , who were treated at our institution during the two treatment eras.
Patients and methods

Patients
Between 1980 and 1996, 299 patients less than 21 years of age were enrolled in four successive trials at this center (AML-80, AML-83, AML-87 and AML-91) for the treatment of newly diagnosed AML. 11, 12, 15, 16 Diagnoses were based on standard morphologic, cytochemical, and immunophenotypic studies of leukemic cells. The Institutional Review Board approved all treatment protocols, and informed consent was obtained from patients, parents, or guardians, as appropriate.
Cytogenetic analyses were performed according to the methods previously described. 17 Chromosomal abnormalities were identified and classified according to the International System for Human Cytogenetic Nomenclature (ISCN). 18 Of the 299 patients, 294 had successful cytogenetic studies. Nineteen of the 294 (6.5%) were found to have an inv (16) . None was found to have a t (16;16) . Nine patients were treated during era 1 (1980 to 1987) on the institutional protocols AML-80 (n = 4) and AML-83 (n = 5), and 10 were treated during era 2 (1988 to 1997) on AML-87 (n = 5) and AML-91 (n = 5).
Statistical analysis
Differences between the two groups of patients in the distribution of clinical and biological features were analyzed by the two-tailed Fisher's exact test for categorical variables and by Student's two sample t-test for continuous variables. Lifetable estimates of the probability of event-free survival (EFS) and overall survival (OS) were derived by the method of Kaplan and Meier and were compared by using the exact logrank test. The duration of EFS was defined as the interval between the date of protocol entry and the first treatment failure of any kind (hematological, CNS or extramedullary relapse, or death), or the date of the last follow-up examination. The duration of OS was defined as the interval between the date of protocol entry and the date of death or last followup examination. All estimates of outcome were reported within one standard error (s.e.). The standard errors were obtained using the method of Peto et al.
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Results
The median duration of follow-up for the eight surviving patients was 8.2 years (range, 2.2 to 16.8 years). Table 1 shows patient characteristics at the time of diagnosis, the treatment received, and the outcome. Nine patients were male and 10 female. The median age at the time of diagnosis was 11.6 years (range, 0.7 to 18.2 years) and median leukocyte count was 29.5 × 10 9 /l (range, 1.3 to 249 × 10 9 /l). Leukemia cell morphology was classified as M4Eo in 13 cases, M2 in two cases, and M1, M4, M5 and M7 in one case each. Leukemia cells expressed CD2 in six of the 13 cases tested.
Eleven cases had additional chromosomal abnormalities. Notably, an extra chromosome 22 was observed in eight of the cases (Table 1) , including one with i(22q) (case No. 17, Table 1 ). 20 Two of the cases with +22 also had either a +8 (patient No. 15) or a +9 (patient No. 11). Of the eight cases with inv(16) and a +22, six are still alive; including the only survivor from era 1. Another patient with inv(16) had a +21 as the sole numerical chromosomal abnormality (patient No. 3). Six cases had additional random structural chromosomal abnormalities, which included a case with a t(X;22)(p22;q11.2) (patient No. 18).
There was no significant difference between patients treated in the two eras in the prevalence of M4 or M5 FAB subtype (P = 1.0), CNS involvement at the time of diagnosis (P = 0.65) presenting white blood cell count (P = 0.67), platelet count (P = 0.19), or gender (P = 0.18). However, the median age at diagnosis of patients treated in era 1 was 13.8 years, while that of patients treated in era 2 was 6.1 years (P = 0.05). . All patients in both treatment eras entered complete remission (CR) with remission induction therapy. The post-remission therapy varied between the different treatment protocols and is described in detail elsewhere. 11, 12, 15, 16 In brief, patients who were treated on AML-80 protocol were eligible for allogeneic bone marrow transplantation after achieving remission if they have an HLA compatible donor and agree to transplantation. Patients who did not undergo transplantation received sequential intensive post-remission therapy for approximately 12 months.
11 Postremission therapy on AML-83 protocol comprised administration of 16 treatment cycles of 6 weeks duration. Each cycle contained three paired drug combinations. 12 Patients treated on AML-87 protocol received three additional cycles of combination chemotherapy as consolidation, but no maintenance therapy. 15 As mentioned above, post-remission therapy on AML-91 consisted of bone marrow transplantation or one course of consolidation therapy. 16 Only one patient treated in era 1 remains alive at the time of this review. The other eight children died of relapsed leukemia (n = 7) or of sepsis during remission (n = 1). By contrast, only three patients treated during era 2 have died, two of infection during CR and one of BMT-related toxicity. The estimated probability of 6-year EFS (±s.e.) was 41 ± 11% for the group as a whole. However, as shown in Figure 1 , patients treated in era 2 had significantly better treatment outcome (P = 0.034); the 6-year EFS estimates was 70 ± 15% as compared Table 2 Initial remission induction therapy in four AML study protocols 
Study
Figure 1
Estimated probability of event-free survival of patients with AML and inv (16) according to treatment era. to 11 ± 7% for patients in era 1. Patients treated in era 2 also had significantly higher probability of survival (6-year OS, 70 ± 15% vs 11 ± 7% in era 1 (P = 0.045)).
To investigate the role of the dose intensity of chemotherapy in the differing outcomes of eras 1 and 2, we calculated the cumulative doses of Ara-C, VP-16 and daunorubicin used during remission induction on the four treatment protocols. As shown in Table 3 , the total doses of Ara-C and VP-16 used in AML-87 were much higher than those used in the two earlier treatment protocols. In AML-91, although the total doses of Ara-C and VP-16 were comparable to those of era 1 protocols, patients received one or two courses of 2-CDA in the 'upfront window' before remission induction therapy began.
Discussion
This small single institutional study of newly diagnosed children and adolescents with AML and inversion 16 highlights Table 3 Cumulative doses of Ara-C and VP-16 given during remission induction therapy in eras 1 and 2
Era and
Ara a One to two courses of 2-chlorodeoxyadenosine (2-CDA) were given in the 'up-front window' before remission induction therapy.
the crucial importance of effective chemotherapy even in this good-prognosis subset of patients. The inv(16)(p13;q22) was found in 6.5% of patients with newly diagnosed AML at our institution, a frequency comparable to the 6% to 7% proportion found in other studies of childhood AML. 6, 7, 9 Because this chromosomal rearrangement is difficult to detect with conventional cytogenetic studies if the quality of the chromosome preparation is suboptimal, its frequency is likely to be higher than reported. 21 Reverse-transcriptase polymerase chain reaction (RT-PCR) is a sensitive technique that can be used to detect the product of the CBF␤-MYH11 fusion gene generated by the inversion. 21, 22 The availability of this method and of commercially available probes to detect inv (16) by fluorescence in situ hybridization should facilitate more accurate detection of chromosome 16 abnormalities in future prospective studies. 23, 24 It is noteworthy that while most of our cases were of the AML FAB-M4Eo subtype, some cases had an M1, M2, M4, M5, or M7 phenotype. This finding confirms the previous reports that inv (16) is not restricted to the M4 subtype of AML. 10, 25 The T associated marker CD2 was expressed in the leukemic blasts of six (46%) of the 13 patients tested in this series. These findings are consistent with the high CD2 expression previously described in AML with inv(16). 26 In this small series of patients treated at a single institution, there was a significant difference in treatment outcome between patients treated in two eras. The greater probability of survival in era 2 cannot be attributed solely to improvements in supportive care, because relapsed or progressive disease, rather than infection, was the main cause of death among patients treated in era 1. The increased probability of survival may reflect the higher dose intensity of Ara-C and VP-16 used in AML-87 and the administration of 2-CDA in an 'up-front window' in AML-91. The activity of 2-CDA against childhood AML, 27,28 especially AML with the FAB M5 morphology or inv (16) , has been previously demonstrated. 29 Several studies have shown an association between highdose Ara-C chemotherapy and improved outcomes in adult patients with AML with inv(16) or t(8; 21) (q22; q22). 13, 14, 30 These studies used larger doses of Ara-C (1.5 g/m 2 to 3 g/m 2 per dose for six doses) than were used in our era 2 protocols. However, one study found that even 400 mg/m 2 Ara-C per day for 5 days provides some survival advantage.
14 The Ara-C dose intensity used in AML-87 was comparable to an intermediate level used in reported adult regimens. 13, 30 AML-87 also employed much higher doses of VP-16 than were used in adult studies, whereas AML-91 used a cumulative dose of Ara-C comparable to the 400 mg/m 2 regimen used in adults. Although our study had a small number of patients, the good outcomes of patients treated in era 2 may be associated with the higher doses of Ara-C and VP-16 on AML-87 and the use of 2-CDA in AML-91.
The 70% estimated probability of 6-year EFS for patients with inv(16) who were treated in era 2 compares favorably with the 58.2% 4-year EFS estimate recently reported for the Pediatric Oncology Group (POG) 8821 trial 9 and the 61% 5-year survival estimate for children and adults with inv(16) treated on the Medical Research Council (MRC) AML10 trial. 7 The Berlin-Frankfurt-Mü nster (BFM) group recently reported a 5-year EFS estimate of 61% for pediatric AML with favorable cytogenetic features, including inv (16) . 8 The MRC AML10 trial reported a 7-year disease-free survival estimate of 59% for children with good-risk AML, including those with inv (16). 31 POG 8821 used high-dose Ara-C in the remission induction phase and VP-16 during consolidation, 32 whereas the MRC and BFM trials used VP-16 (cumulative doses of 1000 to 1500 mg/m 2 ) during induction remission and high-dose Ara-C during consolidation. It is difficult to establish the role of a single agent in the good outcomes of patients with inv(16) in these trials. However, all of these studies used high-dose Ara-C during induction or consolidation. The use of VP-16 during induction in the MRC and BFM trials may have contributed to the overall good results as well.
The higher survival estimates for patients treated during era 2 are unlikely to reflect the use of BMT. No statistically significant difference was found between the small number of patients who underwent transplantation and those who received only chemotherapy during eras 1 and 2 (P = 0.65), and two of the three deaths in era 2 occurred after allogeneic bone marrow transplantation.
In conclusion, this small single-institution study of children and adolescents offers evidence suggesting that pediatric patients who have AML with inv(16) may benefit from Ara-C dose intensification as do adults and that high doses of VP-16 may substantially improve the outcomes of this subset of patients. Further, our findings suggest that 2-CDA, an agent shown to be active against childhood AML (especially monocytic or myelomonocytic subtype), and, more recently, adult Langerhans cell histiocytosis, a monocytic disease, 33 may play Leukemia a role in the improved outcomes of patients with AML and inv (16) . Larger studies are needed to confirm our findings. Our results also underscore the fact that effective treatment is crucial to the survival of patients, even if they have favorable prognostic features.
